Drug Safety Update - Ingenol mebutate gel (Picato▼): suspension of licence due to risk of skin malignancy

This alert advises ingenol mebutate gel should not be prescribed and alternative treatment options for actinic keratosis should be considered. The licence has been suspended while the EMA investigates an increased incidence of benign and malignant skin tumours with the drug.


Medicines and Healthcare products Regulatory Agency